pcwong

    • pcwongpcwong
      ·2023-03-17
      [强] 
      Sorry, this post has been deleted
      279Comment
      Report
    • pcwongpcwong
      ·2023-01-18
      [微笑]

      Tiger Trade Desktop 8.4: New Features You Should Know

      @TigerPM
      Update Info[Hot] Newly added ladder trading tool for all investment products[New] Newly added at-auction order for HK stocks[Optimization] Support percentage enter for stop orderThe introduction of New Features1.[Hot] Newly added ladder trading tool for all investment productsGlad to introduce the new flash order function on Tiger PC! Now you can order your favorite target lightning-fast with just a single click. With our flash order feature, you'll never waste time setting amount and quantity again. Simply click the "price" button, and your purchase will be on its way.Flash Order Offers the Following Benefits:Never miss a trade opportunity again with instant order execution: Create Limit, Stop orders with a single click.Eliminate the stress of trading with a straightforward view chart:Vie
      Tiger Trade Desktop 8.4: New Features You Should Know
      369Comment
      Report
    • pcwongpcwong
      ·2023-01-09
      293Comment
      Report
    • pcwongpcwong
      ·2022-10-25
      [微笑]

      菁良基因GeneWell完成數千萬元B輪融資,華大鬆禾天使基金、隆平生物等參投

      @投资界
      投資界10月25日消息,菁良基因科技(深圳)有限公司(以下簡稱菁良基因)完成了數千萬元的B輪融資,本輪由華大鬆禾天使基金、隆平生物、鍥鏤投資等機構投資。 本輪融資後,菁良基因將進一步推動體外分子診斷檢測第三方質控品的開發及應用,擴大產品的商業化範圍。在醫療領域,菁良基因將加速產品應用落地,爲更多檢測和開發提供高質量的質控支持。菁良基因也將加大品牌傳播和市場推廣力度,進一步加速全球化業務的佈局,填補國際市場在分子診斷標準品領域的空白。 菁良基因成立於2018年1月,是全球提供分子診斷標準品的研發創新型的高科技企業。精準醫療亟需標準的建立。菁良基因通過自主研發的高科技平臺,提供全球領先的產品和服務,致力於提高基因檢測準確率,助力精準醫學快速發展。 除醫療領域外,菁良基因將把在國際上累積的先進經驗帶入農業領域,攜手隆平生物在農業領域建立一系列標準,以分子育種行業市場需求爲導向,集聚雙方優勢資源,共同開展分子育種相關標準品的開發,打破國際壟斷。助力我國農業領域基因檢測的快速發展和分子育種研發和產業化。 分子診斷行業缺乏定性、定量的標準,該問題嚴重製約着我國分子檢測行業的發展。菁良基因創始團隊曾在2011年於英國劍橋開發出全球首個基因檢測標準品。後爲了解決國內標準缺失的問題,於2018年落地深圳,以市場需求爲導向,自主研發爲基礎,基於自身核心技術,推出了多款全球首創的領先產品,填補了國內外體外分子檢測標準品的空白。目前,菁良基因團隊規模已近100人,在深圳、北京、上海等地均設有團隊。 菁良基因先後在腫瘤基因檢測、遺傳病、無創產前篩查、傳感染疾病的檢測領域建立了一系列創新標準品。 菁良基因CEO李菁華博士表示“體外檢測是生物行業發展的關鍵環節,而當前全球體外檢測行業均沒有統一的標準,這是中國生物產業面臨的重要問題和關鍵契機。菁良基因在體外檢測標準品和質控品板塊有着深厚的技術積累和廣泛的
      菁良基因GeneWell完成數千萬元B輪融資,華大鬆禾天使基金、隆平生物等參投
      285Comment
      Report
    • pcwongpcwong
      ·2022-10-15
      [微笑] 
      @Korer
      🐹🐯🐯🐹🐯 老虎的霸氣勇往直前 自信,認定就不放棄 tiger tiger tiger 對你又愛又恨, 🙏🙏🙏希望一直漲漲漲, 虎友們加入分享可以贏 硬幣 @m022mht9 @xiaochoochoo @陳小碩 @A___如___ @孟浩 @toger @Keeley @大天 @Aaa1 @達達集團 @L_8497 @__V______ @慧擇
      🐹🐯🐯🐹🐯 老虎的霸氣勇往直前 自信,認定就不放棄 tiger tiger tiger 對你又愛又恨, 🙏🙏🙏希望一直漲漲漲, 虎友們加入分享可以贏 硬幣 @m022mht9 @xiaochoochoo @陳小碩 @A___如___ @孟浩 @toger @Keeley @大天 @Aaa1 @達達集團 @L_8497 @__V______ @慧擇
      689Comment
      Report
    • pcwongpcwong
      ·2022-05-30
      good

      Valuations are becoming reasonable

      @jayc
      $NVIDIA Corp(NVDA)$On the valuation side, Nvidia still has a "best-in-class" premium over its smaller competitors. In terms of expected P/E ratio, NVIDIA still has a value of 30x, compared to its rival $AMD(AMD)$with an expected P/E ratio of 22x, while other competitors also have relatively low expected P/E ratios, with $Texas Instruments(TXN)$at 19x, $Intel(INTC)$at 12x.Currently, the 1-year valuation of NVIDIA stock is significantly below the mean level and is in the region of the lowest 1-year level. Some analysts believe this suggests that if the latest results and earnings guidance can equal or even exceed market
      Valuations are becoming reasonable
      857Comment
      Report
    • pcwongpcwong
      ·2022-02-10
      943Comment
      Report
    • pcwongpcwong
      ·2022-02-09
      846Comment
      Report
    • pcwongpcwong
      ·2021-04-25
      Good trade
      Sorry, this post has been deleted
      957Comment
      Report
    • pcwongpcwong
      ·2021-04-25
      Up up
      663Comment
      Report
       
       
       
       

      Most Discussed

       
       
       
       
       

      Company: TTMF Limited. Tech supported by Xiangshang Yixin.

      Email:uservice@ttm.financial